Notch2 receptor overexpression has been related to chemoresistance and EMT in pancreatic cancer, and high Notch3 expression is considered as a predictor of poor survival in pancreatic cancer patients, whereas low expression of Notch3 correlated with longer OS in patients with unresectable pancreatic cancer and could serve as a predictive biomarker of gemcitabine efficiency [577,578]. Here, NOTCH3 is linked to pancreatic neoplasm.